Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis

Cited by (1,481)

Items 401–500 of 1,481

1. Does Lowering Low‐Density Lipoprotein Cholesterol With Statin Restore Low Risk in Middle‐Aged Adults? Analysis of the Observational MESA Study
   Kiang Liu, John T. Wilkins, Laura Anne Colangelo, Donald M. Lloyd‐Jones · 2021 · Journal of the American Heart Association
2. The Association of Dietary Cholesterol and Fatty Acids with Dyslipidemia in Chinese Metropolitan Men and Women
   Zhenni Zhu, Fan Wu, Ye Lu, Zhengyuan Wang, Jiajie Zang, Huiting Yu, Changyi Guo, Xiaodong Jia, Xianbiao Shen, Gangqiang Ding · 2018 · Nutrients
3. Bempedoic Acid, the First-in-Class Oral ATP Citrate Lyase Inhibitor with Hypocholesterolemic Activity: Clinical Pharmacology and Drug–Drug Interactions
   Nicola Ferri, Elisa Colombo, Alberto Corsini · 2024 · Pharmaceutics
4. Colesterol LDL, cuanto más bajo mejor
   Juan Pedro‐Botet, Xavier Pintó · 2019 · Clínica e Investigación en Arteriosclerosis
5. Statins, LDL Cholesterol Control, Cardiovascular Disease Prevention, and Atherosclerosis Progression: A Clinical Perspective
   Lorenzo Nesti, Alessandro Mengozzi, Andrea Natali · 2019 · American Journal of Cardiovascular Drugs
6. Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden
   Ulf Landmesser, Peter Lindgren, Emil Hagström, Ben van Hout, Guillermo Villa, Peter J. Pemberton-Ross, Jorge Arellano, Maria K Eriksson Svensson, Mahendra Sibartie, Gregg C. Fonarow · 2020 · European Heart Journal - Quality of Care and Clinical Outcomes
7. The effect of meal frequency on biochemical cardiometabolic factors: A systematic review and meta-analysis of randomized controlled trials
   Shima Abdollahi, Asma Kazemi, Russell J. de Souza, Cain C. T. Clark, Sepideh Soltani · 2021 · Clinical Nutrition
8. Inhibitors of Protein Convertase Subtilisin/Kexin 9 (PCSK9) and Acute Coronary Syndrome (ACS): The State-of-the-Art
   Gabriella Iannuzzo, Marco Gentile, Alessandro Bresciani, Vania Mallardo, Anna Di Lorenzo, Pasquale Merone, Gianluigi Cuomo, Mario Pacileo, Filippo Maria Sarullo, Elio Venturini et al. · 2021 · Journal of Clinical Medicine
9. Target Populations and Treatment Cost for Bempedoic Acid and PCSK9 Inhibitors: A Simulation Study in a Contemporary CAD Cohort
   Christopher M. Blaum, Fabian J. Brunner, Alina Goßling, Friederike Kroeger, Benjamin Bay, Thiess Lorenz, Annika Graef, Tanja Zeller, Renate B. Schnabel, Peter Michael Clemmensen et al. · 2021 · Clinical Therapeutics
10. Effects of almond on cardiometabolic outcomes in patients with type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials
    Seyedeh Parisa Moosavian, Mehran Rahimlou, Mahnaz Rezaei Kelishadi, Sajjad Moradi, Cyrus Jalili · 2022 · Phytotherapy Research
11. Common and Rare PCSK9 Variants Associated with Low-Density Lipoprotein Cholesterol Levels and the Risk of Diabetes Mellitus: A Mendelian Randomization Study
    Lung‐An Hsu, Ming‐Sheng Teng, Semon Wu, Hsin‐Hua Chou, Yu‐Lin Ko · 2022 · International Journal of Molecular Sciences
12. Secondary Cardiovascular Prevention after Acute Coronary Syndrome: Emerging Risk Factors and Novel Therapeutic Targets
    Angelo Silverio, Francesco Paolo Cancro, Luca Esposito, Michele Bellino, Debora D’Elia, Monica Verdoia, Maria Giovanna Vassallo, Michele Ciccarelli, Carmine Vecchione, Gennaro Galasso et al. · 2023 · Journal of Clinical Medicine
13. Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease: Results from the EUROASPIRE IV survey
    Delphine De Smedt, Lieven Annemans, Guy De Backer, Kornelia Kotseva, Lars Rydén, David Wood, Philippe Amouyel, Jan Bruthans, Renata Cífková, Johan DE SUTTER et al. · 2018 · International Journal of Cardiology
14. Effectiveness of a Novel Nutraceutical Compound Containing Red Yeast Rice, Polymethoxyflavones and Antioxidants in the Modulation of Cholesterol Levels in Subjects With Hypercholesterolemia and Low-Moderate Cardiovascular Risk: The NIRVANA Study
    Paolo Cimaglia, Francesco Vieceli Dalla Sega, Francesco Vitali, Veronica Lodolini, Davide Bernucci, Giulia Passarini, Francesca Fortini, Luisa Marracino, Giorgio Aquila, Paola Rizzo et al. · 2019 · Frontiers in Physiology
15. Association of baseline LDL-C with total and cardiovascular mortality in patients using proprotein convertase subtilisin-kexin type 9 inhibitors: A systematic review and meta-analysis
    Safi Ullah Khan, Haris Riaz, Hammad Rahman, Muhammad U. Khan, Muhammad Shahzeb Khan, Mohamad Adnan Alkhouli, Edo Kaluski, Thorsten Martin Leucker, Michael Joseph Blaha · 2019 · Journal of clinical lipidology
16. Efficacy of red yeast rice extract on myocardial infarction patients with borderline hypercholesterolemia: A meta-analysis of randomized controlled trials
    Bunleu Sungthong, Chenchira Yoothaekool, Sornsalak Promphamorn, Wiraphol Phimarn · 2020 · Scientific Reports
17. Efficacy and Safety of Armolipid Plus®: An Updated PRISMA Compliant Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials
    Cicero, Arrigo F. G., Kennedy, Cormac, Knežević, Tamara, Bove, Marilisa, Georges, Coralie M. G., Šatrauskienė, Agnė, Toth, Peter P., Fogacci, Federica · 2021 · Nutrients
18. In-silico trial emulation to predict the cardiovascular protection of new lipid-lowering drugs: an illustration through the design of the SIRIUS programme
    Denis Angoulvant, Solène Granjeon-Noriot, Pierre Amarenco, Alexandre Bastien, Emmanuelle Béchet, Franck Boccara, Jean‐Pierre Boissel, Bertrand Cariou, Eulalie Courcelles, Alizée Diatchenko et al. · 2024 · European Journal of Preventive Cardiology
19. The Role of Non-HDL Cholesterol and Apolipoprotein B in Cardiovascular Disease: A Comprehensive Review
    Vasiliki K. Katsi, Nikolaos Argyriou, Christos Fragoulis, Konstantinos P Tsioufis · 2025 · Journal of Cardiovascular Development and Disease
20. Number of Patients Eligible for PCSK9 Inhibitors Based on Real-world Data From 2.5 Million Patients
    Alberto Zamora, L. Masana, Marc Comas‐Cufí, Núria Plana, Àlex Vila, Maria García-Gil, Lia Alves‐Cabratosa, Roberto Elosúa, Jaume Marrugat, Rafel Ramos · 2018 · Revista Española de Cardiología (English Edition)
21. Lipid management in ACS: Should we go lower faster?
    Bariş Gencer, François Mach · 2018 · Atherosclerosis
22. Common gene variants in ASGR1 gene locus associate with reduced cardiovascular risk in absence of pleiotropic effects
    Lubna Ali, Arjen J. Cupido, Maaike Rijkers, G. Kees Hovingh, Adriaan Georgius Holleboom, Geesje M. Dallinga‐Thie, Erik S.G. Stroes, Marjolein A.W. van den Boogert · 2020 · Atherosclerosis
23. Inclisiran: A New Pharmacological Approach for Hypercholesterolemia
    Stefania Angela Di Fusco, Aldo Pietro Maggioni, Chiara Bernelli, Francesco Perone, Vincenzo De Marzo, Edoardo Conte, Francesca Musella, Giuseppe Uccello, Leonardo De Luca, Domenico Gabrielli et al. · 2022 · Reviews in Cardiovascular Medicine
24. Updates in Small Interfering RNA for the Treatment of Dyslipidemias
    Stefano Carugo, Cesare Riccardo Sirtori, Guido Gelpi, Alberto Corsini, Lale S Tokgözoğlu, Massimiliano Ruscica · 2023 · Current Atherosclerosis Reports
25. Alternative lipid lowering strategies: State-of-the-art review of red yeast rice
    Lorenzo Buzzelli, Andrea Segreti, Daniela Di Gioia, Erika Lemme, Maria Rosaria Squeo, Antonio Nenna, Giuseppe Di Gioia · 2023 · Fitoterapia
26. Development and validation of alternative cardiovascular risk prediction equations for population health planning: a routine health data linkage study of 1.7 million New Zealanders
    Suneela Mehta, Rod Jackson, Romana D. Pylypchuk, Katrina Poppe, Sue Wells, Andrew Kerr · 2018 · International Journal of Epidemiology
27. Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review
    Eliano Pio Navarese, Felicita Andreotti, Paolo Raggi, Michalina Marta Kołodziejczak, Antonino Buffon, Kevin P. Bliden, Udaya S. Tantry, Jacek Kubica, Gennaro Sardella, Alexander Lauten et al. · 2018 · European Heart Journal - Cardiovascular Pharmacotherapy
28. Regression with a right‐censored predictor using inverse probability weighting methods
    Roland Matsouaka, Folefac Atem · 2020 · Statistics in Medicine
29. The Effect of Inflammation and Insulin Resistance on Lipid and Lipoprotein Responsiveness to Dietary Intervention
    Kristina S. Petersen, Kate J. Bowen, Alyssa M. Tindall, Valerie K. Sullivan, Emily A. Johnston, Jennifer A Fleming, Penny M. Kris‐Etherton · 2020 · Current Developments in Nutrition
30. Optimal Target Level of Low-density Lipoprotein Cholesterol for Vascular Function in Statin Naïve Individuals
    Shogo Matsui, Masato Kajikawa, Eisuke Hida, Tatsuya Maruhashi, Yumiko Iwamoto, Akimichi Iwamoto, Nozomu Oda, Shinji Kishimoto, Takayuki Hidaka, Yasuki Kihara et al. · 2017 · Scientific Reports
31. Which lipids should be analyzed for diagnostic workup and follow-up of patients with hyperlipidemias?
    Langlois, Michel R., Nordestgaard, Børge G. · 2018 · Current Cardiology Reports
32. Homogeneización de los valores del perfil lipídico
    Juan Pedro‐Botet, Luis Rodrı́guez Padial, Carlos Brotons, Margarita Esteban-Salán, Aurora García-Lerín, Xavier Pintó, Iñaki Lekuona, Jordi Ordóñez‐Llanos · 2017 · Clínica e Investigación en Arteriosclerosis
33. Clinical guidelines of the Russian Medical Society on arterial Hypertension (RSH) and the Eurasian association of Cardiologists (EaC) for the diagnosis and treatment of arterial hypertension (2024)
    Irina Evgen'evna Chazova, Чихладзе Новелла Михайловна, Nataliya V. Blinova, Аксенова Анна Владимировна, Tatiana A. Alekseeva, Lali G. Ambatiello, Yu. А. Balanova, Anna E. Bragina, Nikolai M. Danilov, O. M. Drapkina et al. · 2024 · Systemic Hypertension
34. Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era
    Marc Steven Sabatine, Robert Patrick Giugliano · 2017 · JAMA Cardiology
35. LDL cholesterol: How low to go?
    Chris J. Packard · 2017 · Trends in Cardiovascular Medicine
36. The Effects of Calculated Remnant-Like Particle Cholesterol on Incident Cardiovascular Disease: Insights from a General Chinese Population
    Yanli Chen, Guangxiao Li, Xiaofan Guo, Nanxiang Ouyang, Zhao Li, Ning Ye, Shasha Yu, Hongmei Yang, Yingxian Sun · 2021 · Journal of Clinical Medicine
37. Clinical profiles and outcomes of acute ST-segment elevation myocardial infarction in young adults in a tertiary care center in Saudi Arabia
    Haitham I. Sakr, Ahmed S. Azazy, Ali Hillani · 2021 · Saudi Medical Journal
38. Association between low-density lipoprotein cholesterol and sudden cardiac arrest in people with diabetes mellitus
    Yun Gi Kim, Joo Hee Jeong, Kyungdo Han, Seung‐Young Roh, Kyongjin Min, Hyoungsuk Lee, Yun Young Choi, Jaemin Shim, Jong‐Il Choi, Young‐Hoon Kim · 2023 · Cardiovascular Diabetology
39. 2022 Saudi Guidelines for the Management of Dyslipidemia
    Jamilah Saad Alrahimi, Shukri M. AlSaif, Mirvat A. Alasnag, Zuhier Ahmed Awan, Fawaz Almutairi, Hajer Y. Al Mudaiheem, Bariş Gencer, Alberico Luigi Catapano, François Mach, Adel Abdulkader Tash · 2023 · Heart Views
40. The relationship between residual cholesterol risk and plaque characteristics in patients with acute coronary syndrome: Insights from an optical coherence tomography study
    Yanan Gao, Yake Lou, Yuyang Liu, Sijing Wu, Ziwei Xi, Xu Wang, Yujie Zhou, Wei Liu · 2020 · Atherosclerosis
41. Predictive value of triglyceride/high-density lipoprotein cholesterol for major clinical outcomes in advanced chronic kidney disease: a nationwide population-based study
    Yaerim Kim, Soojin Lee, Yeonhee Lee, Min Woo Kang, Sehoon Park, Sang Hyun Park, Kyungdo Han, Jin Hyuk Paek, Woo Yeong Park, Kyubok Jin et al. · 2020 · Clinical Kidney Journal
42. Cross-Talk between Lipoproteins and Inflammation: The Role of Microvesicles
    Gemma Chiva‐Blanch, Lina Badimón · 2019 · Journal of Clinical Medicine
43. Efficacy and safety of bempedoic acid alone or combining with other lipid-lowering therapies in hypercholesterolemic patients: a meta-analysis of randomized controlled trials
    Xiang Zhao, Xu-biao Ma, Xing Luo, Zhihua Shi, Ziwen Deng, Yuanxiang Jin, Zhipeng Xiao, Liming Tan, Pingfang Liu, Shilong Jiang et al. · 2020 · BMC Pharmacology and Toxicology
44. Effect of statins on lipid metabolism-related microRNA expression in HepG2 cells
    Álvaro Cerda, Raul Hernandes Bortolin, Victor Manríquez, Luis Antonio Salazar, Tomás Zambrano, Cristina Moreno Fajardo, Mário Hiroyuki Hirata, Rosário Dominguez Crespo Hirata · 2021 · Pharmacological Reports
45. Fixed-dose combination of rosuvastatin and ezetimibe: treating hypercholesteremia according to cardiovascular risk
    Vivencio Barrios, Carlos Escobar · 2021 · Expert Review of Clinical Pharmacology
46. Nurse-led, telephone-based follow-up after acute coronary syndrome yields improved risk factors after 36 months: the randomized controlled NAILED-ACS trial
    Robin Henriksson, Daniel Huber, Thomas Mooe · 2021 · Scientific Reports
47. Effects of a gluten-reduced or gluten-free diet for the primary prevention of cardiovascular disease
    Christine M. Schmucker, Angelika Eisele‐Metzger, Joerg J Meerpohl, Cornelius Lehane, Daniela Kuellenberg de Gaudry, Szimonetta Lohner, Lukas Schwingshackl · 2022 · Cochrane Database of Systematic Reviews
48. Novel theranostic approaches to neovascularized atherosclerotic plaques
    Christie A. Boswell-Patterson, Marie‐France Hétu, Stephen Ching-ng Pang, Julia E. Herr, Jianhua Zhou, Shagun Jain, Alexander Bambokian, Amer M. Johri · 2023 · Atherosclerosis
49. Effects of a Novel Nutraceutical Combination (Aquilea Colesterol®) on the Lipid Profile and Inflammatory Biomarkers: A Randomized Control Trial
    Mónica Doménech, Rosa Mª Casas, Ana María Ruiz-León, Javier Sobrino, Emilio Ros, Ramón Estruch · 2019 · Nutrients
50. Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand
    Khachen Kongpakwattana, Zanfina Ademi, Thanaputt Chaiyasothi · 2019 · PharmacoEconomics
51. Cholesterol and Egg Intakes, and Risk of Hypertension in a Large Prospective Cohort of French Women
    Conor‐James MacDonald, Anne‐Laure Madika, Fabrice Bonnet, Guy Fagherazzi, Martín Lajous, Marie‐Christine Boutron‐Ruault · 2020 · Nutrients
52. Therapeutic Agents Targeting Cardiometabolic Risk for Preventing and Treating Atherosclerotic Cardiovascular Diseases
    Benoît J. Arsenault, Nicolas Perrot, Rishi Puri · 2018 · Clinical Pharmacology & Therapeutics
53. Association of haptoglobin phenotype with incident acute myocardial infarction in Chinese patients with type 2 diabetes
    Resham L Gurung, M Yiamunaa, Sylvia Liu, Jianjun Liu, Clara Chan, Robin Wai Munn Choo, Keven Ang, Chee Fang Sum, Tavintharan Subramaniam, Su Chi Lim · 2019 · Cardiovascular Diabetology
54. Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies
    Catapano, Alberico L., Mikhailova, Elina, Navar, Ann Marie, Banka, Puja, Corral, Pablo, Saxena, Manish, Steg, P. Gabriel, Verma, Subodh, Kordahi, Andrew Yacoub, Mendizabal, Geraldine et al. · 2026 · JACC
55. Multifaceted Role of Apolipoprotein C3 in Cardiovascular Disease Risk and Metabolic Disorder in Diabetes
    Pan, Bo-Yi, Chen, Chen-Sheng, Chen, Fang-Yu, Shen, Ming-Yi · 2024 · International Journal of Molecular Sciences
56. High Density Lipoprotein Particle Composition, Functionality, Deficiency, and Atherosclerotic Cardiovascular Disease Risk: A Review
    Ernst J. Schaefer, Bela F. Asztalos, Tomáš Vaisar, Margaret R. Diffenderfer, H Bryan Brewer, Eveline Oestreicher Stock, John P. Kane · 2025 · Current Atherosclerosis Reports
57. Effect of statin treatment on circulating malondialdehyde concentrations: a systematic review and meta-analysis
    Angelo Zinellu, Panagiotis Paliogiannis, Maria Franca Usai, Ciriaco Carru, Arduino Aleksander Mangoni · 2019 · Therapeutic Advances in Chronic Disease
58. Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction With Statins, Ezetimibe, and PCSK9 Inhibition
    Daniel P. Marcusa, Robert Patrick Giugliano, Jeong‐Gun Park, James A. de Lemos, Christopher Paul Cannon, Marc Steven Sabatine · 2020 · JAMA Cardiology
59. Canned Beans Decrease Serum Total and LDL Cholesterol in Adults with Elevated LDL Cholesterol in a 4-wk Multicenter, Randomized, Crossover Study
    Katarina M. Doma, Karen F olinar, D. Dan Ramdath, Thomas M. S. Wolever, Alison M. Duncan · 2021 · Journal of Nutrition
60. Myocardial Infarction, Stroke, and All-Cause Mortality according to Low-Density Lipoprotein Cholesterol Level in the Elderly, a Nationwide Study
    You‐Bin Lee, Minji Koo, Eunjin Noh, Soon Young Hwang, Jung A Kim, Eun Roh, So‐hyeon Hong, Kyung Mook Choi, Sei Hyun Baik, Geum Joon Cho et al. · 2022 · Diabetes & Metabolism Journal
61. Is it Time for Single-Pill Combinations in Dyslipidemia?
    François Schiele, Leopoldo Pérez de Isla, Marcello Arca, Charalambos V. Vlachopoulos · 2021 · American Journal of Cardiovascular Drugs
62. Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk
    Rishi Raj Rikhi, Michael David Shapiro · 2022 · Journal of Clinical Medicine
63. Association between cholesterol levels and dementia risk according to the presence of diabetes and statin use: a nationwide cohort study
    You‐Bin Lee, Min Young Kim, Kyungdo Han, Bongsung Kim, Jiyun Park, Gyuri Kim, Kyu Yeon Hur, Jae Hyeon Kim, Sang‐Man Jin · 2022 · Scientific Reports
64. An update on the nutritional profiles of quinoa (Chenopodium quinoa Willd.), amaranth (Amaranthus spp.), and chia (Salvia hispanica L.), three key species with the potential to contribute to food security worldwide
    Enrique Olmos, Inmaculada Román-García, María Reguera, Camilo Alexander Mestanza Uquillas, Nieves Fernández‐García · 2022 · JSFA reports
65. Using a Metabotype Framework to Deliver Personalized Nutrition Improves Dietary Quality and Metabolic Health Parameters: A 12‐Week Randomized Controlled Trial
    Elaine Hillesheim, Xiaofei Yin, Geetha Priya Sundaramoorthy, Lorraine Brennan · 2023 · Molecular Nutrition & Food Research
66. Butein ameliorates chronic stress induced atherosclerosis via targeting anti-inflammatory, anti-fibrotic and BDNF pathways
    Mujeeba Rehman, Rishabh Chaudhary, Sonu Rajput, Vipul Agarwal, Arjun Singh Kaushik, Siddhi Srivastava, Sukriti Srivastava, Rohit Singh, Irfan Aziz, Sanjay Pratap Singh et al. · 2023 · Physiology & Behavior
67. Reducing saturated fat intake lowers LDL-C but increases Lp(a) levels in African Americans: the GET-READI feeding trial
    Hayley G. Law, Muhammad Arif Khan, Wei Zhang, Heejung Bang, Jennifer Carlton Rood, Marlene M. Most, Michael Lefevre, Lars Berglund, Byambaa Enkhmaa · 2023 · Journal of Lipid Research
68. Sebelipase alfa improves atherogenic biomarkers in adults and children with lysosomal acid lipase deficiency
    Don P. Wilson, Mark Friedman, Sachin Marulkar, Tyler Hamby, Éric Bruckert · 2018 · Journal of clinical lipidology
69. Plasma lipoproteins in posttraumatic stress disorder patients compared to healthy controls and their associations with the HPA- and HPT-axis
    Giel‐Jan de Vries, Roel J. T. Mocking, Johanna Assies, Aart H. Schene, Miranda Olff · 2017 · Psychoneuroendocrinology
70. Effects of Non-statin Lipid-Modifying Agents on Cardiovascular Morbidity and Mortality Among Statin-Treated Patients: A Systematic Review and Network Meta-Analysis
    Thanaputt Chaiyasothi, Surakit Nathisuwan, Piyameth Dilokthornsakul, Prin Vathesatogkit, Ammarin Thakkinstian, Christopher Michael Reid, Wanwarang Wongcharoen, Nathorn Chaiyakunapruk · 2019 · Frontiers in Pharmacology
71. Trends in cholesterol testing during the COVID-19 pandemic
    Esra D. Gumuser, Sara Haidermota, Phoebe Finneran · 2021 · American Journal of Preventive Cardiology
72. Lipids, Apolipoproteins, and Inflammatory Biomarkers of Cardiovascular Risk: What Have We Learned?
    David Rhainds, Mathieu R. Brodeur, Jean‐Claude Tardif · 2018 · Clinical Pharmacology & Therapeutics
73. Maximizing the benefits of cholesterol-lowering drugs
    Kenneth R. Feingold · 2019 · Current Opinion in Lipidology
74. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: comparing and contrasting guidance across the Atlantic
    Marc Steven Sabatine · 2016 · European Heart Journal
75. Circulating metabolites associated with incident myocardial infarction and stroke: A prospective cohort study of 90 438 participants
    Canqing Yu, Shu‐Fen Chen, Ya-Ru Zhang, Hui-Fu Wang, Shu‐Yi Huang, Shi‐Dong Chen, Yue‐Ting Deng, Bang‐Sheng Wu, Kevin Kuo, Rongze Wang et al. · 2022 · Journal of Neurochemistry
76. Standard modifiable cardiovascular risk factors in patients with acute coronary syndrome: A report from multicenter percutaneous coronary intervention registry
    Juri Iwata, Taku Inohara, Yasuyuki Shiraishi et al. · 2023 · Journal of Cardiology
77. Long-Lasting Control of LDL Cholesterol Induces a 40% Reduction in the Incidence of Cardiovascular Events: New Insights from a 7-Year Study
    Valentina Trimarco, Raffaele Izzo, Paola Gallo, Maria Virginia Manzi, Imma Forzano, Daniela Pacella, Gaetano Santulli, Bruno Trimarco · 2023 · Journal of Pharmacology and Experimental Therapeutics
78. Nurse-Led Strategy to Improve Blood Pressure and Cholesterol Level Among People With HIV
    Chris Todd Longenecker, Kelley A. Jones, Corrilynn O. Hileman et al. · 2024 · JAMA Network Open
79. Dyslipidemia Treatment and Cerebrovascular Disease: Evidence Regarding the Mechanism of Stroke
    Sang Hee Ha, Bum Joon Kim · 2024 · Journal of Lipid and Atherosclerosis
80. Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab
    Yanyan Zhang, Zhaohui Pei, Beijian Chen, Yanling Qu, Xiaolin Dong, Binge Yu, Guoqin Wang, Fang Xu, Dongmei Lu, Zhimei He et al. · 2024 · Pharmacological Research
81. Baseline Characteristics of Participants in STAREE: A Randomized Trial for Primary Prevention of Cardiovascular Disease Events and Prolongation of Disability‐Free Survival in Older People
    Sophia Zoungas, Chris Moran, Andrea J. Curtis, Simone Spark, Zachary Flanagan, Lawrence Joseph Beilin, Trevor T.‐J. Chong, Geoffrey C. CLOUD, Ingrid Hopper, Alissia Kost et al. · 2024 · Journal of the American Heart Association
82. The economic impact of familial hypercholesterolemia on productivity
    Zanfina Ademi, Clara Marquina, Ella Zomer, Cate Bailey, Alice J. Owen, Jing Pang, Richard Norman, Gerald Francis Watts, Danny Liew · 2020 · Journal of clinical lipidology
83. Role of Lipid-Lowering Therapy in Low-Density Lipoprotein Cholesterol Goal Attainment: Focus on Patients With Acute Coronary Syndrome
    Qinqin Wang, Chun Liang · 2020 · Journal of Cardiovascular Pharmacology
84. Transcriptional analysis for cholesterol-lowering effects of marine Lactobacillus plantarum Lp10 isolated from kelp
    Zhiwei Ye, Tianfen Guo, Can Tang, Yue Yuan, Yi D. Zhao, Jun Lu, Jun‐Fang Lin, Li‐Qiong Guo · 2020 · LWT
85. The Disposition and Metabolism of Bempedoic Acid, a Potent Inhibitor of ATP Citrate Lyase, in Healthy Human Subjects
    Benny M. Amore, Clay T. Cramer, Diane Elaine MacDougall, Maurice G. Emery · 2023 · Drug Metabolism and Disposition
86. PCSK9 Inhibition to Reduce Cardiovascular Risk
    David D. Waters, Priscilla Y. Hsue · 2017 · Circulation Research
87. Efficacy of alirocumab for reducing plaque vulnerability: Study protocol for ALTAIR, a randomized controlled trial in Japanese patients with coronary artery disease receiving rosuvastatin
    Hiromasa Otake, Yoichiro Sugizaki, Takayoshi Toba, Yuichiro Nagano, Yoshiro Tsukiyama, Kenichi Yanaka, Hiroyuki Yamamoto, Akira Nagasawa, Hiroyuki Onishi, Ryo Takeshige et al. · 2018 · Journal of Cardiology
88. Management of Dyslipidemia in Women and Men with Coronary Heart Disease: Results from POLASPIRE Study
    Małgorzata Setny, Piotr Jankowski, Agnieszka Krzykwa, Karol Adam Kamiński, Zbigniew Gąsior, Maciej Haberka, Danuta Czarnecka, Andrzej Pająk, Paweł Kozieł, Karolina Szóstak-Janiak et al. · 2021 · Journal of Clinical Medicine
89. Irisin in atherosclerosis
    Zhe-Bin Cheng, Liang Huang, Xuan Xiao, Jia-Xiang Sun, Zi-Kai Zou, Jie-Feng Jiang, Cong Lu, Hai-Ya Zhang, Chi Zhang · 2021 · Clinica Chimica Acta
90. New Treatment Targets and Innovative Lipid-Lowering Therapies in Very-High-Risk Patients with Cardiovascular Disease
    Achim Leo Burger, Edita Pogran, Marie Muthspiel, Christoph Clemens Kaufmann, Bernhard Jäger, Kurt Huber · 2022 · Biomedicines
91. Long-term effects of e-Health secondary prevention on cardiovascular health: a systematic review and meta-analysis
    Jing Jing Su, Justina Yat Wa Liu, Daphne Sze Ki Cheung, Shanshan Wang, Martin Christensen, Patrick Pui Kin Kor, Stefanos Tyrovolas, Angela Yee Man Leung · 2023 · European Journal of Cardiovascular Nursing
92. VLDL receptor gene therapy for reducing atherogenic lipoproteins
    Ronald M. Krauss, Jonathan T. Lu, Joseph J Higgins, Cathryn M. Clary, Ray Tabibiazar · 2023 · Molecular Metabolism
93. Inflammation compared to low-density lipoprotein cholesterol: two different causes of atherosclerotic cardiovascular disease
    Benjamin Nilsson Wadström, Kasper Mønsted Pedersen, Anders Berg Wulff, Børge Grønne Nordestgaard · 2023 · Current Opinion in Lipidology
94. Lipid-Lowering Efficacy of Combination Therapy With Moderate-Intensity Statin and Ezetimibe Versus High-Intensity Statin Monotherapy: A Randomized, Open-Label, Non-Inferiority Trial From Korea
    Hyejung Choi, Si‐Hyuck Kang, Sang-Woo Jeong, Chang‐Hwan Yoon, Tae‐Jin Youn, Woo Hyuk Song, Dong Woon Jeon, Sang Wook Lim, Jun-Hee Lee, Seong-Wook Cho et al. · 2023 · Journal of Lipid and Atherosclerosis
95. HDL as a Treatment Target: Should We Abandon This Idea?
    Floran Bègue, Marie Laurine Apalama, Gilles C. Lambert, Olivier Meilhac · 2023 · Current Atherosclerosis Reports
96. Consensus document on diagnosis and management of familial hypercholesterolemia from the Italian Society for the Study of Atherosclerosis (SISA)
    Patrizia Tarugi, Stefano Bertolini, Sebastiano Calandra, Marcello Arca, Francesco Angelico, Manuela Casula, Angelo Baldassare Cefalu, Laura D’Erasmo, Giuliana Fortunato, Pasquale Perrone Filardi et al. · 2024 · Nutrition Metabolism and Cardiovascular Diseases
97. Recipe for Heart Health: A Randomized Crossover Trial on Cardiometabolic Effects of Extra Virgin Olive Oil Within a Whole‐Food Plant‐Based Vegan Diet
    Andrea M. Krenek, Anne Mathews, Juen Guo, Amber B. Courville, Carl J. Pepine, Stephanie Therese Chung, Monica Aggarwal · 2024 · Journal of the American Heart Association
98. Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome
    Doron Zahger, Gregory G. Schwartz, Weiming Du, Michael J. Szarek, Deepak L. Bhatt, Vera Bittner, Andrzej Budaj, Rafael Díaz, Shaun G. Goodman, J. Wouter Jukema et al. · 2024 · Journal of the American College of Cardiology
99. Association of lipoprotein(a) and major adverse cardiovascular events in patients with percutaneous coronary intervention
    Zhihao Chen, Chaohui Jiang, Huimin Qu, Shuang Liang, Jian Yang, Hui Wu, Chao He, Xinan Wang · 2018 · Archives of Medical Science
100. Current and future role of lipoprotein(a) in preventive cardiology
     Adam N. Berman, Ron Blankstein · 2019 · Current Opinion in Cardiology